68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

Official record

Identifier

NCT07760012

Recruiting locations

country

China

Interventions studied

68Ga-SorB PET/CT

Lead sponsor

Peking University Third Hospital

Target enrolment

50 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Aug 12, 2026

Last updated on the registry

Aug 12, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* \- Adults aged 18 to 75 years.
* Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate hematologic, hepatic, renal, and coagulation function:
* White blood cell count ≥ 4.0 × 10\^9/L or absolute neutrophil count ≥ 1.5 × 10\^9/L;
* Platelet count ≥ 100 × 10\^9/L;
* Hemoglobin ≥ 90 g/L;
* PT or APTT ≤ 1.5 × upper limit of normal (ULN);
* Total bilirubin ≤ 1.5 × ULN;
* ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases);
* ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases);
* Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN.
* Normal cardiac function.
* Estimated life expectancy of at least 12 weeks.
* Willing and able to comply with study procedures and follow-up.
* At least one measurable target lesion according to RECIST version 1.1.
* Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET/CT imaging.
* Clinically indicated to undergo 18F-FDG PET/CT for tumor evaluation.
* Able to understand the study procedures and provide written informed consent.

Exclusion Criteria:

* Pregnant or breastfeeding women.
* Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate.
* Inability to tolerate PET/CT imaging or complete study follow-up.
* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Indexed under

Liver Cancer